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The involvement of the hypothalamic-pituitary-adrenal axis in the control of body fluid homeostasis has been extensively
investigated in the past few years. In the present study, we reviewed the recent results obtained using different approaches to
investigate the effects of glucocorticoids on the mechanisms of oxytocin and vasopressin synthesis and secretion in response
to acute and chronic plasma volume and osmolality changes. The data presented here suggest that glucocorticoids are not only
involved in the mechanisms underlying the fast release but also in the transcriptional events that lead to decreased synthesis and
secretion of these neuropeptides, particularly oxytocin, under diverse experimental conditions of altered fluid volume and
tonicity. The endocannabinoid system, through its effects on glutamatergic neurotransmission within the hypothalamus and the
nuclear factor κB-mediated transcriptional activity, seems to be also involved in the specific mechanisms by which glucocorti-
coids exert their central effects on neurohypophyseal hormone synthesis and secretion.
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Introduction
The control of body fluid homeostasis involves com-
plex mechanisms that regulate water and electrolyte in-
gestion and excretion. It is well established that plasma
osmolality is mainly regulated by water balance, while
sodium, which is one of the major components of the
extracellular compartment, is a determinant factor for the
maintenance of blood volume. Specific areas in the central
nervous system (CNS) implicated in the control of hydro-
mineral homeostasis receive information from specialized
systems that detect peripheral changes in both volume
and tonicity of extracellular fluid. The baroreceptors, lo-
cated in the cardiovascular system, are activated in re-
sponse to changes in blood volume or blood pressure and
the nucleus of the solitary tract (NTS) plays a key role in the
integrative responses that reach the forebrain, particularly
the hypothalamus. On the other hand, the osmosensitive
areas are located in the circumventricular organs and the
presence of both osmo- and sodium-sensitive neurons in
these nuclei has been well characterized. Increases of 1-
2% in plasma osmolality stimulate water drinking and also
enhance neurohypophyseal secretion of vasopressin (AVP)
and oxytocin (OT). Conversely, a 10% decrease in blood
volume is known to increase AVP secretion.
The control of volume and osmolality of mammalian
body fluids occurs in response to stimuli that arise
from both the intracellular and extracellular compartments.
This information is conveyed to specific areas of the CNS
responsible for an integrated response, which is depend-
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ent on the integrity of the third ventricle anteroventral
region, which comprises the organum vasculosum of lamina
terminalis, the ventral portion of the median preoptic nucle-
us (MnPO) and the subfornical organ (SFO). These struc-
tures, once stimulated, can determine responses that in-
volve 1) the behavioral induction of thirst or salt appetite, or
both, 2) changes in sympathetic and renal nerve activity, 3)
activation of the renin-angiotensin-aldosterone system, or
4) secretion of AVP and OT from the neurohypophysis, and
5) secretion of natriuretic peptides from the heart.
Both AVP and OT are produced by magnocellular neu-
rons of the paraventricular (PVN) and supraoptic (SON)
nuclei of the hypothalamus and stored in terminals located in
the neurohypophysis. AVP is mostly known for its antidi-
uretic effects, but it is also involved in the thermoregulatory
and cardiovascular responses (1). The activation of the V2
vasopressinergic receptors in the kidneys leads to increased
permeability to water and consequent fluid reabsorption
along the distal nephron. A stimulatory action of AVP on
atrial natriuretic peptide (ANP) release has also been pro-
posed (2). OT was shown to act either directly on the kidneys
to promote sodium excretion or by an indirect pathway,
stimulating ANP release from the heart (3,4). The participa-
tion of the natriuretic peptidergic system in response to
hypervolemia and hyperosmolality has been well estab-
lished also in the brain (5, for a review, see Ref. 6).
The prototype of the natriuretic peptides is the circulat-
ing peptide containing 28 amino acids (ANP 99-126 amino
acids), which is processed from the atrial prohormone (1-
126 amino acids). Other members of the natriuretic peptide
family are BNP, CNP and urodilatin. The natriuretic pep-
tides act at the cell membrane level through three types of
receptors (NPR-A, NPR-B, and NPR-C). NPR-A and NPR-
B, but not NPR-C, have an intracellular guanylate cyclase
domain that generates cyclic guanosine monophosphate
(cGMP) from guanosine triphosphate, which in turn acti-
vates protein kinase G (7). In contrast, NPR-C is likely to
act as a clearance receptor and to remove natriuretic
peptides from the circulation (8). Recently, it has also been
shown to have physiological effects on the heart and
vasculature (9). The expression of NPR-A, analyzed by
RT-PCR, was detected in all kidney layers (6).
The natriuretic effects of OT occur through a dual
mechanism: generation of nitric oxide (NO) in the kidney,
leading to increased cGMP and, at higher doses, induction
of ANP release from the heart that, in turn, also increases
cGMP. Oxytocin-induced natriuresis occurs mainly through
a cGMP-mediated decrease in tubular Na+ reabsorption. In
contrast to ANP, which increases cGMP in the renal ves-
sels as well as in the tubules, OT acts through its receptors
located in NOergic cells identified in the macula densa and
proximal tubules, increasing cGMP production and closing
Na channels. Thus, both ANP- and OT-induced natriuresis
and kaliuresis appear to be mediated by cGMP (6).
The renin-angiotensin-aldosterone system also plays
an important role in the regulation of body fluid homeosta-
sis. An interaction between the angiotensinergic pathways
and neurohypophyseal secretion has been described (6).
Lauand et al. (10) recently showed that intracerebroven-
tricular administration of angiotensin II (ANG II) increases
AVP and OT secretion and also activates neurons in
hypothalamic areas related to the control of fluid homeo-
stasis. Several hormones (ANG II, AVP, OT, ANP, and
mineralocorticoids) injected into the anterior hypothala-
mus of the rat modify neuronal activity and appear to be
involved in the regulation of fluid and electrolyte balance.
ANG II induces a delayed sodium appetite following water
intake (11). It has been suggested that an active inhibitory
system may exist to restrain NaCl intake. Peptides and
hormones with the opposite effect to that of ANG II on fluid
and electrolyte balance, such as ANP, may attenuate ANG
II-induced salt appetite (6). It has also been demonstrated
that pre-treatment with an OT receptor antagonist increases
NaCl intake induced by intracerebroventricular injection of
ANG II, without significant changes in water intake, sug-
gesting an inhibitory action of OT on salt appetite (12).
Taken together, these data provided a link between the
central mechanisms controlling body fluid homeostasis
and the peripheral adjustments of renal and cardiovascu-
lar systems in response to acute increases in plasma
volume and osmolality.
Significant progress has been made to identify the
neural circuits involved in the physiological and behavioral
osmoregulatory responses. There is growing evidence for
the participation of the hypothalamic-pituitary-adrenal (HPA)
axis in the adaptive responses following changes in blood
volume and osmolality. The presence of the cytoplasmic
glucocorticoid receptor (GR) has already been reported in
the SON (13) and also in the parvocellular portion of the
PVN, where this receptor is predominantly co-expressed
with corticotrophin-releasing factor (CRF) (14). Further-
more, AVP and OT are weak secretagogues of adrenocor-
ticotropic hormone (15-17), strongly suggesting an inter-
action between the HPA axis and the secretion of neurohy-
pophyseal hormones.
Glucocorticoids - general aspects
Glucocorticoids are essential for normal development
and to regulate not only stress responses but also meta-
bolic and immunologic mechanisms (18,19). The main
actions of the glucocorticoids are mediated by the cytoso-
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lic GR, which, in the absence of the endogenous ligand, is
assembled into a multiprotein complex (20). Although re-
tained in the cytoplasm, this conformation enables high-
affinity ligand binding.
Produced by the adrenal glands under the stimulation
of the HPA axis, the glucocorticoids act as ligand-depend-
ent transcription factors that positively regulate genes
through interaction with DNA enhancer sequences, called
glucocorticoid response elements (GREs) (21-23). The
activated GR was also shown to negatively regulate the
expression of inflammatory genes through direct protein-
protein interaction with proinflammatory transcription fac-
tors, without DNA binding (24,25).
The genomic and long-term mechanisms that follow
glucocorticoid binding to the cytoplasmic GR and nuclear
entry are also known as the classic pathway, but recent
evidence suggests that fast glucocorticoid actions are
mediated by membrane receptors and activation of nonge-
nomic signaling events. In fact, glucocorticoids have been
reported to bind specifically to cell membrane sites and to
induce electrolytic movement changes (26,27). Although
the molecular characterization of these receptors remains
to be established in humans, a functional corticosterone
membrane-associated receptor was identified in the am-
phibian brain (28).
The expression of GR in CRF-expressing neurons in
the parvocellular PVN reinforces the direct feedback ac-
tion of glucocorticoid in the control of CRF synthesis and
release (14,29). Co-localization of mineralocorticoid re-
ceptor (MR) and GR was also observed in the parvocellu-
lar region, but not in the magnocellular region of the PVN
(30). These results suggest that MR and GR may interact
in the control of HPA axis activity.
There are several lines of evidence showing that
glucorticoid action is modulated by the presence of 11ß-
hydroxysteroid dehydrogenases (11ß-HSDs) in several tis-
sues (31). 11ß-HSD1 activates cortisone to cortisol to facili-
tate GR-mediated action. In addition, 11ß-HSD2 plays an
important role in aldosterone target tissues where it cata-
lyzes the opposite reaction (i.e., inactivation of cortisol to
cortisone) to prevent activation of MR by cortisol. Therefore,
11ß-HSD activity allows aldosterone occupancy of MR by
inactivating endogenous glucocorticoids. In the kidney, 11ß-
HSD2 is mainly expressed in collecting ducts, where it is co-
localized with MR. Inhibition of 11ß-HSD2 can result in
glucocorticoid-dependent mineralocorticoid excess and hy-
pertension. This enzyme is also found in several tissues that
are not classic targets for mineralocorticoids, such as peri-
and circumventricular regions and NTS. Therefore, tissue-
specific glucorticoid metabolism may be involved in the
control of fluid balance and blood pressure.
Effects of glucocorticoids on neurohypophyseal
hormone secretion
Several studies from our laboratory have demonstrated
that isotonic (0.9% NaCl) blood volume expansion (BVE)
increases plasma concentrations of OT and ANP and
decreases plasma AVP levels, resulting in increased wa-
ter and sodium excretion. On the other hand, rats submit-
ted to hypertonic (1.8% NaCl) BVE presented increased
plasma levels of AVP, OT and ANP in order to promote
water reabsorption and renal sodium excretion (32-34).
In 2004, Durlo et al. (33) reported the first evidence for
the participation of the HPA axis in hormone secretion
induced by BVE in rats. These investigators reported that
both hypervolemia and hyperosmolality increased plasma
corticosterone concentrations, an event also known to
occur in response to other types of stress, such as forced
swimming, immobilization and hypoglycemia (35). This
study also demonstrated that pre-treatment with dexa-
methasone, a synthetic glucocorticoid, blunted OT, but not
ANP secretion, induced by BVE. These results were con-
firmed by Ruginsk et al. (34), who also showed that previ-
ous administration of dexamethasone did not alter AVP
secretion in response to isotonic and hypertonic BVE. Pre-
treatment with dexamethasone also decreased the secre-
tion of OT but not AVP induced by central angiotensinergic
and cholinergic stimulation (10).
Taken together, these results suggest that, besides
their genomic action on the modulation of transcriptional
events, glucocorticoids are likely to present a fast negative
modulation of OT but not AVP release from neurohypophy-
seal stores. In fact, Limbourg and Liao (36) reported that
glucocorticoids could exert short-term effects on NO pro-
duction in the heart, contributing to vasodilatatory responses
during ischemic conditions. These data suggested that
glucocorticoids may have actions that depend on non-
genomic mechanisms, since the effects are rapidly ob-
served.
Additionally, the HPA axis also seems to be involved in
the mechanisms underlying chronic adjustments to os-
motic challenges. Berghorn et al. (37) reported that long-
term hyperosmolality induced an increase in the number of
receptors for glucocorticoids in magnocellular vasopressi-
nergic cells. Furthermore, increased plasma corticoster-
one levels were also reported in response to salt loading
(38-40). These investigators also suggested that the HPA
responsiveness to either CRF or AVP seems to be im-
paired after long-term osmotic stimulation.
One of the most studied neuromodulators that mediate
the effects of the HPA axis on neurohypophyseal hormone
secretion is NO, although the use of very distinct ap-
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proaches has been generating conflicting results. Ventura
et al. (40) demonstrated that the increase in plasma OT
and AVP induced by salt loading was accompanied by an
increased NO synthase activity in the SON and PVN,
although the previous administration of NO synthase in-
hibitor produced different effects on the secretion of these
peptides. These data indicate that NO differentially modu-
lates the secretion of neurohypophyseal hormones in re-
sponse to chronic salt loading.
Effects of glucocorticoids on hypothalamic
neuronal activation
The detection of immediate-early gene products, such
as Fos nuclear protein, has been used extensively as a
marker of neuronal activation (41). The number of Fos-
positive neurons in the PVN and SON was increased in rats
submitted to hypertonic BVE and this effect was observed in
parallel with enhanced neurohypophyseal secretion of AVP
and OT (34). Furthermore, the use of specific antibodies has
also allowed the identification of neuron phenotype, which is
of interest to clarify the particular cellular mechanisms in-
volved in response to a specific stimulus. Data obtained by
Godino et al. (42) and extended by results from our labora-
tory (34) have shown that hypertonic BVE induced increased
numbers of vasopressinergic and oxytocinergic neurons
activated in both the PVN and SON. On the other hand, the
number of oxytocinergic, but not vasopressinergic, magno-
cellular neurons activated in these nuclei was increased in
rats submitted to isotonic BVE.
The responsiveness of magnocellular neurosecretory
cells to plasma hyperosmolality is subject to inputs from the
osmosensitive neurons (43), which are also activated by
administration of hypertonic solution. A significant number of
these neurons project to the hypothalamic magnocellular
nuclei and other areas involved in the regulation of body fluid
homeostasis, since hypertonicity also increases the number
of Fos-positive neurons in the SFO, central nucleus of the
amygdala, parabrachial nucleus, locus coeruleus, ventrolat-
eral medulla, NTS, and area postrema (42). The activation of
these areas depends on intact osmosensory pathways and
mediates the autonomic, endocrine and behavioral responses
involved in the osmoregulation (44).
The glucocorticoids seem to be also involved in the
mechanisms underlying magnocellular neuronal activa-
tion following BVE. Ruginsk et al. (34) showed that, be-
sides inhibiting hormone secretion, pre-treatment with dexa-
methasone decreased the number of oxytocinergic neu-
rons activated in response to both isotonic and hypertonic
BVE. This inhibitory effect induced by dexamethasone
was observed on vasopressinergic neurons following hy-
pertonic but not isotonic BVE. We also demonstrated that
Fos expression and plasma AVP levels were both in-
creased by osmotic, cholinergic and angiotensinergic cen-
tral stimulation. However, dexamethasone pre-treatment
induced a decrease of Fos expression in the MnPO, PVN
and SON, but did not affect AVP secretion. Therefore, it
appears that Fos expression and AVP secretion were
parallel events that occurred in response to a given stimu-
lus, rather than interacting with one another (10). The
apparent divergence between unaltered AVP secretion
and decreased neuronal activity observed in dexametha-
sone-pretreated rats subjected to hypertonic BVE or os-
motic, cholinergic and angiotensinergic central stimulation
suggests that the glucocorticoids may differentially modu-
late the AVP release from neurohypophyseal storages and
the de novo hormone synthesis in the PVN and SON.
According to some other studies, glucocorticoid ac-
tions on magnocellular hypothalamic neurons seem to be
predominantly inhibitory. Di et al. (45,46) proposed that
corticosterone could act on transmembrane G-coupled
receptors and stimulate the release of endocannabinoids
in the hypothalamus. According to these investigators, the
endocannabinoids would act as retrograde messengers
and not only inhibit the release of glutamate, the main
excitatory neurotransmitter in the CNS, but also stimulate
the release of gamma-aminobutyric acid (GABA), contrib-
uting to the decreased activity of both parvocellular and
magnocellular hypothalamic neurons.
Results obtained in our laboratory indicate that there is
an increase in total glutamate content in the PVN and SON
of rats submitted to BVE and this response is not altered by
dexamethasone pre-treatment, suggesting that the bal-
ance between neurotransmitter production and release
would not be affected in this condition (47). These results
confirm the crucial role of glutamate in mediating the
responses to hypervolemia and hyperosmolality.
Lopes da Silva et al. (48) also suggested that dexameth-
asone is likely to inhibit the expression of AVP and OT
mRNA in the hypothalamic PVN and SON of rats submitted
to water restriction and salt loading. The participation of the
nuclear factor κB (NFκB) in the mediation of glucocorticoid
actions in transcriptional events has also been investigated
by our group. The presence of its phosphorylated p85 sub-
unit in the PVN and SON after water deprivation and salt
loading was also observed (Lopes da Silva A, unpublished
data) and this evidence strongly supports the hypothesis
that this pathway is involved in the effects of glucocorticoids
on AVP and OT release. Therefore, these data indicate that
glucocorticoids may act on different points of gene transcrip-
tion and protein synthesis, from neuronal activation and
neurotransmitter balance to hormone secretion.
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Discussion
In the experimental models of BVE, water restriction
and salt loading, the autonomic, neuroendocrine, cardio-
vascular, renal and behavioral systems are recruited to
restore body fluid homeostasis (6,49). A better under-
standing of these mechanisms has been obtained with the
recent contributions of molecular studies, but many of the
events at the ultrastructural level are still unknown. The
participation of the HPA axis, particularly the glucocorti-
coids, in mediating the responses to plasma volume and
osmolality changes seems to involve diverse mechanisms
ranging from the control of molecular aspects within the
CNS to systemic modulation of hormone release, as sum-
marized in Figure 1.
The glucocorticoid interaction with DNA binding sites
has been well characterized and may also be activated
after the acute stimulus or under prolonged exposure to
stress. A GRE was identified in target genes (50) and by
DNA sequence analysis, several elements upstream to the
transcriptional start point of the rat OT gene were identi-
fied, matching the consensus sequence of enhancers
inducible by glucocorticoids (51). Therefore, the observed
effect of prolonged dexamethasone pre-treatment, reduc-
ing OT mRNA content and the consequent hormone se-
cretion, could be due to an inhibition of OT gene transcrip-
tion. The presence of GREs is speculated in the AVP gene,
although no relevant result has been reported thus far.
The participation of the NFκB cascade in the transcrip-
tional events evoked by glucocorticoids is also a promising
area of study, although many pathways are known to
converge to this common point. Additionally, the involve-
ment of the nitrergic system in the mediation of AVP and
OT release represents a growing area of investigation,
since NO seems to differentially regulate the release of
both neuropeptides.
The study of the pharmacological benefits of cannabis-
like substances was described very early in medical sci-
ences, but it was only in 1988 that the cannabinoid CB1
receptor was described in the CNS. The main endogenous
ligands for this type of receptor are anandamide and 2-
arachidonoylglycerol and a clear relationship between the
predominant anatomical localization of CB1 receptors in
the CNS and the cognitive, affective and motor systems
was then established (52). Since then, the endocannab-
inoids have been extensively studied in the mediation of
homeostatic responses, such as those related to energy
balance, pain and behavior.
Hartman et al. (53) reported the first evidence for the in
vivo participation of the cannabinoid system in the control
of body fluid homeostasis. This study demonstrated that
previous administration of naloxone, an opioid antagonist,
to adult rats enhanced OT but not AVP secretion induced
by hypertonic saline injection. Additionally, these investi-
gators also showed that the central content of OT but not
AVP was depleted in naloxone-pretreated mature rats.
The most recent link between the endocannabinoids and
the neuroendocrine system that controls body fluid ho-
meostasis was obtained from in vitro manipulations of CB1
receptors. The inhibition of the glutamatergic neurotrans-
mission within the hypothalamus by endocannabinoids, as
reported by Di et al. (45,46), provides a new insight into the
molecular mechanisms that may be recruited in the pres-
ence of specific disturbances in body fluid homeostasis.
In conclusion, it has been suggested that the HPA axis
might be involved in the integrative control of body fluid
homeostasis, modulating neurohypophyseal hormone se-
cretion, supporting the idea that the hypothalamus, par-
ticularly the PVN, contains a complex network with specific
and integrative pathways. The advance of new techniques,
such as interference RNA, blocking specific proteins, pep-
tides or neurotransmitters, as well as the data on electro-
physiological studies will provide in the near future useful
tools for the understanding of mechanisms of glucocorti-
coid control of body fluid homeostasis.
Decreased
glutamate release
(cannabinoids)
DNA
interaction
(GREs, NFκB?)
Neuromodulators (NO?)
NeurohypophysisHypothalamus
Increased glucocorticoid secretion
Blood
volume
expansion
Water
restriction
Salt
loading
Decreased
neuronal
activation
Decreased
hormone
synthesis
Decreased hormone
secretion (store)
Figure 1. Schematic representation of glucocorticoid actions in
the CNS in response to blood volume expansion, water restric-
tion and salt loading. GREs = glucocorticoid response elements;
NFκB = nuclear factor κB; NO = nitric oxide.
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